Liquidia prices 3.49M shares at $7.16 in underwritten public offering

Liquidia Corporation has priced an underwritten public offering of 3,491,620 shares of common stock at a public offering price of $7.16 for total gross proceeds of approximately $25M, before deducting underwriting discounts and commissions and expenses payable by Liquidia. The offering is expected to close on December 14, 2023, subject to customary closing conditions. BofA Securities acted as the sole book-running manager for the offering. BTIG acted as lead manager. Net proceeds from the offering are expected to fund ongoing commercial development of YUTREPIA inhalation powder, continue development of YUTREPIA in other clinical trials, including but not limited to trials for WHO Group 3 patients and pediatric patients, clinical development of L606 and for general corporate purposes.